Nutlin-3a and the Next Logic of p53 Translation

2026-09-20

Nutlin-3a offers a precise way to interrogate MDM2–p53 biology while opening a translational conversation about ferroptosis, migration, and treatment strategy in glioblastoma. This article connects target engagement with experimental design, model selection, and clinically relevant decision points.

FITC Goat Anti-Mouse IgG (H+L) Antibody Guide

2026-09-19

This fluorescein-conjugated secondary antibody provides fluorescent detection of mouse IgG primary antibodies in immunofluorescence, microscopy, and flow cytometry workflows. It is intended for research assay development and optimization, not as a standalone reagent for detecting non-mouse immunoglobulins or as evidence of a validated clinical diagnostic procedure.

BMPSB4 Activates Autophagy in Corticotroph PitNETs

2026-09-18

A 2024 study identifies BMPSB4 as a pharmacological agonist of deficient BMP4 signaling in corticotroph pituitary neuroendocrine tumors. Using transcriptomic, imaging, cellular, and animal-model evidence, the authors link BMP4/SMAD1/5/9 activation to autophagy-mediated tumor suppression and reduced ACTH and corticosterone output.

Sodium Ascorbate: From ROS Biology to Translation

2026-09-18

A translational perspective on how Sodium Ascorbate can support reproducible ROS-driven cancer research, while biomarker-led models such as circulating GPNMB illustrate the requirements for moving from tumor-cell phenotypes toward precision study design.

Cabozantinib (XL184) in RCC Research Workflows

2026-09-17

Cabozantinib (XL184) supports more than endpoint viability assays: it enables time-resolved studies of RTK suppression, angiogenesis, phosphoproteomic remodeling, and motility adaptation. This workflow translates acute-versus-chronic exposure findings into practical renal cell carcinoma and endothelial assay designs.

Cabozantinib (XL184) RCC Research Workflow

2026-09-17

Build reproducible Cabozantinib experiments that separate acute kinase suppression from chronic adaptation in renal cell carcinoma. This workflow combines phosphoproteomics, MET validation, motility assays, and angiogenesis readouts to turn a multi-target inhibitor into a practical systems-biology tool.

AAL-993: A Decision Framework for Angiogenesis Assays

2026-09-16

AAL-993 is a VEGF receptor inhibitor suited to mechanistically layered angiogenesis studies. This article shows how to connect receptor-level potency, endothelial phenotypes, tumor-model outcomes, and network-pharmacology insights without overstating cross-domain evidence.

Angiotensin (1-7) Experimental Workflows

2026-09-16

Build reproducible Mas-receptor experiments with a defined heptapeptide sequence, practical dosing benchmarks, and assay-ready handling guidance. From renal fibrosis models to receptor-binding studies, this workflow connects mechanism, controls, and troubleshooting without overstating translational evidence.

Reserpine (N1867): Practical Lab Workflow

2026-09-15

Reserpine (SKU N1867) provides a characterized research reagent for controlled neurotransmitter depletion research, antihypertensive mechanism studies, and related neuropharmacology research. This guide addresses identity, solubility, storage, solution preparation, and QC; the compound is for research use only and should not be used for diagnostic, therapeutic, or medical applications.

Crizotinib Hydrochloride in ALK Research

2026-09-15

Crizotinib hydrochloride is an ATP-competitive ALK kinase inhibitor that also targets c-Met and ROS1. Its defined kinase-phosphorylation effects make it useful for cancer biology research, including controlled studies in patient-derived tumor–stroma models.

Preserving Protein Truth in Mitocytosis Research

2026-09-14

Mitocytosis research shows why biological interpretation depends on rigorous protein preservation. This thought-leadership guide connects mitochondrial stress biology with practical sample-preparation strategy, highlighting how an EDTA-free inhibitor cocktail can protect phosphorylation-sensitive and native-protein workflows without overstating preclinical findings.

Fzd5 Links Cholesterol to Wnt Signaling

2026-09-14

Fzd5 Cholesterol Sensing Drives Wnt Signaling in Cancer

2026-09-13

The reference study identifies Frizzled5 as a cholesterol-sensing Wnt receptor that links lipid metabolism to receptor palmitoylation, plasma-membrane trafficking, and pancreatic cancer growth. Its findings provide a mechanistic framework for studying cholesterol-sensitive Wnt signaling and suggest that disrupting the Fzd5–cholesterol interface may be relevant in Wnt-dependent malignancies.

AZD1390: ATM Kinase Inhibitor Workflows

2026-09-12

AZD1390 supports mechanism-guided studies of ATM signaling, radiation response, and replication stress across glioma and lung cancer models. This workflow connects nanomolar ATM inhibition with practical assay design and emerging REV1–DHX36 G-quadruplex biology.

Cy5 Goat Anti-Mouse IgG: Assay Design

2026-09-11

The Cy5 Goat Anti-Mouse IgG (H+L) Antibody provides a versatile fluorescent readout for mouse primary antibodies. This article explains how to deploy it as an analytical layer in osteogenesis and exosome studies, with emphasis on controls, interpretation, and workflow design.